DRUG · Mapped RxNorm record
Palbociclib
Normalized identity: palbociclibView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy
NCT02549430
Drugs and interventions used in this trial
5 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Anastrozole
Normalized identity: anastrozoleView linked drug · Find medicine records ·
Find other trials using this name
DRUG · Mapped RxNorm record
Letrozole
Normalized identity: letrozoleView linked drug · Find medicine records ·
Find other trials using this name
DRUG · Mapped RxNorm record
Exemestane
Normalized identity: exemestaneView linked drug · Find medicine records ·
Find other trials using this name
DRUG · Mapped RxNorm record
Fulvestrant
Normalized identity: fulvestrantView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedTo Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Breast Cancerverified · MONDO: breast cancer
Interventions
PalbociclibDRUG · verified · RxNorm: palbociclib
AnastrozoleDRUG · verified · RxNorm: anastrozole
LetrozoleDRUG · verified · RxNorm: letrozole
ExemestaneDRUG · verified · RxNorm: exemestane
FulvestrantDRUG · verified · RxNorm: fulvestrant
Sponsors & collaborators
Fondazione Sandro Pitiglianilead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02549430 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.